Canlyniadau Chwilio - Christof Schneider

Mireinio'r Canlyniadau
  1. 1
    Molecular pathogenesis of diffuse large B-cell lymphoma

    Molecular pathogenesis of diffuse large B-cell lymphoma gan Christof Schneider, Laura Pasqualucci, Riccardo Dalla‐Favera

    Cyhoeddwyd 2011
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    BCL6 positively regulates AID and germinal center gene expression via repression of miR-155

    BCL6 positively regulates AID and germinal center gene expression via repression of miR-155 gan Katia Basso, Christof Schneider, Qiong Shen, Antony B. Holmes, Manu Setty, Christina Leslie, Riccardo Dalla‐Favera

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    tRNA-derived microRNA modulates proliferation and the DNA damage response and is down-regulated in B cell lymphoma

    tRNA-derived microRNA modulates proliferation and the DNA damage response and is down-regulated in B cell lymphoma gan Roy L. Maute, Christof Schneider, Pavel Sumazin, Antony B. Holmes, Andrea Califano, Katia Basso, Riccardo Dalla‐Favera

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis

    MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis gan Paola Brescia, Christof Schneider, Antony B. Holmes, Qiong Shen, Shafinaz Hussein, Laura Pasqualucci, Katia Basso, Riccardo Dalla‐Favera

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    microRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas

    microRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas gan Christof Schneider, Manu Setty, Antony B. Holmes, Roy L. Maute, Christina Leslie, Lara Mussolin, Angelo Rosolen, Riccardo Dalla‐Favera, Katia Basso

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Identification of the Human Mature B Cell miRNome

    Identification of the Human Mature B Cell miRNome gan Katia Basso, Pavel Sumazin, Pavel Morozov, Christof Schneider, Roy L. Maute, Yukiko Kitagawa, Jonathan Mandelbaum, Joseph Haddad, Chang‐Zheng Chen, Andrea Califano, Riccardo Dalla‐Favera

    Cyhoeddwyd 2009
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells

    Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells gan Katia Basso, Masumichi Saito, Pavel Sumazin, Adam A. Margolin, Kai Wang, Wei-Keat Lim, Yukiko Kitagawa, Christof Schneider, Mariano J. Alvarez, Andrea Califano, Riccardo Dalla‐Favera

    Cyhoeddwyd 2009
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma

    BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma gan Masumichi Saito, Urban Novak, Erich Piovan, Katia Basso, Pavel Sumazin, Christof Schneider, Marta Crespo, Qiong Shen, Govind Bhagat, Andrea Califano, Amy Chadburn, Laura Pasqualucci, Riccardo Dalla‐Favera

    Cyhoeddwyd 2009
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease

    FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease gan Christof Schneider, Ning Kon, Letizia Amadori, Qiong Shen, Friederike H. Schwartz, Benjamin Tischler, Marion Bossennec, David Dominguez-Sola, Govind Bhagat, Wei Gu, Katia Basso, Riccardo Dalla‐Favera

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Acquired <i>BTK</i> mutations associated with resistance to noncovalent BTK inhibitors

    Acquired <i>BTK</i> mutations associated with resistance to noncovalent BTK inhibitors gan Jialei Qi, Sascha Endres, Deyan Y. Yosifov, Eugen Tausch, Rashmi Priyadharshini Dheenadayalan, Xiang Gao, Annika Müller, Christof Schneider, Daniel Mertens, Peter Gierschik, Martin Wist, Billy Michael Chelliah Jebaraj, Stephan Stilgenbauer

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Carta
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)

    Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG) gan Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, Jasmin Bahlo, Sandra Robrecht, Eugen Tausch, Johannes Bloehdorn, Manuela Hoechstetter, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Michael Hallek, Hartmut Döhner, Richard Rosenquist, Paolo Ghia, Κώστας Σταματόπουλος, Stephan Stilgenbauer

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

    IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia gan Annika Scheffold, Billy Michael Chelliah Jebaraj, Eugen Tausch, Johannes Bloehdorn, Paolo Ghia, Anella Yahiaoui, Anna Dolnik, Tamara J. Blätte, Lars Bullinger, Rashmi Priyadharshini Dheenadayalan, Li Li, Christof Schneider, Shih‐Shih Chen, Nicholas Chiorazzi, Sascha Dietrich, Martina Seiffert, Stacey Tannheimer, Hartmut Döhner, Daniel Mertens, Stephan Stilgenbauer

    Cyhoeddwyd 2019
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

    Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study gan Othman Al‐Sawaf, Can Zhang, Tong Lu, Michael Z. Liao, Anesh Panchal, Sandra Robrecht, Travers Ching, Maneesh Tandon, Anna‐Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Sebastian Böttcher, Karl‐Anton Kreuzer, Brenda Chyla, Dale Miles, Clemens‐Martin Wendtner, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

    Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia gan Stephan Stilgenbauer, Eugen Tausch, Andrew W. Roberts, Matthew S. Davids, Barbara Eichhorst, Michael Hallek, Peter Hillmen, Christof Schneider, Johannes Schetelig, Sebastian Böttcher, Arnon P. Kater, Yanwen Jiang, Michelle Boyer, Relja Popovic, Majd T. Ghanim, Michael Moran, Wendy Sinai, Xifeng Wang, Nabanita Mukherjee, Brenda Chyla, William G. Wierda, John F. Seymour

    Cyhoeddwyd 2024
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

    Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia gan H. Huber, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Can Zhang, Eugen Tausch, Christof Schneider, Johannes Bloehdorn, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten Utoft Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL

    NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL gan Alena Sophie Ehrmann, Miguel Quijada‐Álamo, Viola Close, Min Guo, Valentina Carracoi, Claudia Pérez‐Carretero, Luís A. Corchete, Tobias Friedrich, Benedetto Daniele Giaimo, Deyan Y. Yosifov, Johannes Bloehdorn, Alberto Rodríguez‐Sánchez, Eugen Tausch, Christof Schneider, Hartmut Döhner, Thomas Kietzmann, Tilman Borggrefe, Stephan Stilgenbauer, Franz Oswald, Jesús María Hernández‐Rivas, Daniel Mertens

    Cyhoeddwyd 2025
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

    Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax gan Eugen Tausch, Christof Schneider, Sandra Robrecht, Can Zhang, Anna Dolnik, Johannes Bloehdorn, Jasmin Bahlo, Othman Al‐Sawaf, Matthias Ritgen, Anna-Maria Fink, Barbara Eichhorst, Karl‐Anton Kreuzer, Maneesh Tandon, Kathryn Humphrey, Yanwen Jiang, William Schary, Lars Bullinger, Daniel Mertens, M. Porro Lurà, Michael Kneba, Hartmut Döhner, Kirsten Fischer, Michael Hallek, Stephan Stilgenbauer

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

    S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY gan Othman Al‐Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna‐Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl‐Anton Kreuzer, Liliya Sivcheva, Carsten Utoft Niemann, Anthony P. Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Eva Diana Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer

    Cyhoeddwyd 2023
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

    Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia gan Othman Al‐Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl‐Anton Kreuzer, Brenda Chyla, Joseph N. Paulson, Christian P. Pallasch, Lukas P. Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

    Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial gan Othman Al‐Sawaf, Rudy Ligtvoet, Sandra Robrecht, Janina Stumpf, Anna‐Maria Fink, Eugen Tausch, Christof Schneider, Sebastian Böettcher, Martin Mikusko, Matthias Ritgen, Johannes Schetelig, Julia von Tresckow, Ursula Vehling‐Kaiser, Tobias Gaska, Clemens‐Martin Wendtner, Bjoern Chapuy, Kirsten Fischer, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Philipp B. Staber, Carsten Utoft Niemann, Michael Hallek, Barbara Eichhorst

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: